Apogee Therapeutics Prices $350M Offering at $70/Share Following Positive Trial Data
Summary
Apogee Therapeutics has priced its underwritten public offering at $350 million, selling 5 million shares at $70.00 per share. This represents an increase from the previously proposed $300 million offering announced earlier. This capital raise follows the highly positive 52-week Phase 2 clinical trial data for its lead candidate, zumilokibart, which was reported on March 23rd. The substantial capital infusion will significantly bolster the company's financial runway for ongoing clinical development. While the offering is priced at a discount to the current market price, implying some dilution for existing shareholders, it is a strategic move to capitalize on recent positive data and fund future growth. Traders will be watching the market's reaction to the dilution and the company's plans for deploying the newly raised capital.
At the time of this announcement, APGE was trading at $73.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.1B. The 52-week trading range was $26.20 to $84.56. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.